Professor of Internal Medicine, Endocrinology and Diabetes,
University of Michigan
Rodica Pop-Busui, MD, PhD, is the Larry D. Soderquist Professor of Diabetes, a prominent diabetologist at Michigan Medicine and a recognized leader in the field of diabetes and diabetes complications. She is the Vice Chair for Clinical Research in the Department of Internal Medicine and the Director of Clinical Research, Mentoring and Development of the M-Diabetes at the University of Michigan. Her research interests involve the chronic complications of diabetes, diabetic peripheral and cardiovascular autonomic neuropathy, nephropathy and cardiovascular disease, and novel technologies for treating type 1 diabetes.
Dr. Pop-Busui has published over 160 peer-reviewed manuscripts and book chapters, and received awards from the Fulbright Foundation, the American Diabetes Association (ADA), and the University of Michigan. She has been an elected to Chair the ADA Scientific Research Review Clinical, the Research Committee of the landmark DCCT/EDIC study, and to chair the Diabetes & Cardiovascular Disease Interest Group. She is also one of the principal investigators in the recently established NIDDK Diabetes Foot Consortium.
She has contributed her research efforts and leadership to some of the most important national and international diabetes clinical trials to date including: the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the following NIDDK-funded trials: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications, A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes (“PERL), “Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE), Bypass Angioplasty Revascularization Diabetes 2 (BARI- 2D), Targeting Inflammation with Salsalate for Type 2 Diabetes (TINSAL T2D), and many others funded by Foundations and Industry such as the Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE), Wireless Innovation for Seniors with Diabetes Mellitus (WISDM), or REPLACE-BG.
Disclosure: Disclosure information not submitted.